Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Magendra Thakur

Pulmonary Disease Massena, NY Medical Doctor

NPI 1427074343 CMS profile 246346

1 Hospital Dr, Massena, NY 13662

Open in the dashboard

General payments

$60,643

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Magendra Thakur of Massena, NY is reported in the CMS Open Payments database as having received $60,643 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $532 14
2024 General $482 19
2023 General $20,322 26
2022 General $16,155 24
2021 General $11,540 30
2020 General $9,379 58
2019 General $2,233 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Magendra Thakur
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Magendra Thakur were reported at $532. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Magendra Thakur Pulmonary Disease median Middle half National median
2019 $2,233 $377 $109–$1,340 $163
2020 $9,379 $230 $56–$907 $114
2021 $11,540 $269 $68–$1,072 $132
2022 $16,155 $390 $100–$1,457 $149
2023 $20,322 $419 $114–$1,659 $160
2024 $482 $476 $123–$1,818 $164
2025 $532 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $57,130 161 payments
  2. AstraZeneca Pharmaceuticals LP $986 42 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $566 23 payments
  4. Novo Nordisk Inc $431 10 payments
  5. Janssen Pharmaceuticals, Inc $375 10 payments
  6. Genzyme Corporation $326 7 payments
  7. Harmony Biosciences LLC $142 3 payments
  8. Philips Electronics North America Corporation $122 8 payments
  9. Lilly USA, LLC $105 3 payments
  10. Jazz Pharmaceuticals Inc. $102 3 payments
  11. Other $357 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $54,300 20 payments
  2. Food and Beverage $5,950 256 payments
  3. Education $214 7 payments
  4. Travel and Lodging $179 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $27,060 77 payments
  2. ANORO ELLIPTA $1,367 17 payments
  3. FARXIGA $493 11 payments
  4. SYMBICORT $486 19 payments
  5. DUPIXENT $326 7 payments
  6. ANORO $315 24 payments
  7. FASENRA $294 5 payments
  8. OFEV $271 14 payments
  9. NUCALA $245 15 payments
  10. AREXVY $244 5 payments
  11. Other $2,922 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

8,304

Median for Sleep Medicine: 173

Drug cost

$2,277,649

Median for Sleep Medicine: $10,887

Branded share of claims

41%

Median for Sleep Medicine: 17.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 1,009 $1,018,696
Prolastin C Alpha-1-Proteinase Inhibitor Brand 12 $129,272
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 92 $126,063
Ozempic Semaglutide Brand 59 $113,087
Eliquis Apixaban Brand 71 $105,169
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 123 $99,066
Jardiance Empagliflozin Brand 50 $72,252
Mounjaro Tirzepatide Brand 43 $45,818
Breo Ellipta Fluticasone/Vilanterol Brand 75 $44,266
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 32 $40,377

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 723 Part D prescribers listed as Sleep Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$141,401

Of which drugs: $7,390

Medicare patients

651

Average age 73

Services billed

2,819

355 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
COPD 43%
Diabetes 41%
Ischemic heart disease 34%
Heart failure 24%
Chronic kidney disease 23%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 75 75 $4,337
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 21 21 $2,747

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $73
$73 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $67
$67 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $64
$64 1,009 —
AREXVY
  • GlaxoSmithKline, LLC. $58
$58 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $54
$54 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record